<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Homocysteinemia may play an etiologic role in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by promoting <z:mp ids='MP_0003674'>oxidative stress</z:mp>, systemic <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether <z:chebi fb="0" ids="17230">homocysteine</z:chebi>-lowering treatment by B vitamin supplementation prevents the risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: The Women's <z:chebi fb="11" ids="22586">Antioxidant</z:chebi> and <z:chebi fb="9" ids="27470">Folic Acid</z:chebi> Cardiovascular Study (WAFACS), a randomized, double-blind, placebo-controlled trial of 5,442 female health professionals aged &gt; or = 40 years with a history of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) or three or more <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors, included 4,252 women free of <z:mp ids='MP_0002055'>diabetes</z:mp> at baseline </plain></SENT>
<SENT sid="3" pm="."><plain>Participants were randomly assigned to either an active treatment group (daily intake of a combination pill of 2.5 mg <z:chebi fb="9" ids="27470">folic acid</z:chebi>, 50 mg <z:chebi fb="14" ids="27306">vitamin B6</z:chebi>, and 1 mg <z:chebi fb="9" ids="17439">vitamin B12</z:chebi>) or to the placebo group </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: During a median follow-up of 7.3 years, 504 women had an incident diagnosis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, there was no significant difference between the active treatment group and the placebo group in <z:mp ids='MP_0002055'>diabetes</z:mp> risk (relative risk 0.94 [95% CI 0.79-1.11]; P = 0.46), despite significant lowering of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>Also, there was no evidence for effect modifications by baseline intakes of dietary <z:chebi fb="3" ids="37445">folate</z:chebi>, <z:chebi fb="14" ids="27306">vitamin B6</z:chebi>, and <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In a sensitivity analysis, the null result remained for women compliant with their study pills (0.92 [0.76-1.10]; P = 0.36) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Lowering <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels by daily supplementation with <z:chebi fb="9" ids="27470">folic acid</z:chebi> and <z:chebi fb="14" ids="27306">vitamins B6</z:chebi> and <z:chebi fb="13" ids="33611">B12</z:chebi> did not reduce the risk of developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> among women at high risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>